Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit offers insight into the new NCCN guidelines, discusses the new ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

Researchers at Oregon Health & Science University have developed a new blood test that they say is able to detect pancreatic ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Department of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, 3720 15th Avenue NE, Box 355061, Seattle, Washington 98195, United States Seattle Children’s ...

Background PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in ...

4Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. 5Yale Center for Precision Cancer Modeling, Yale School of Medicine, New Haven, Connecticut. 6Department of Immunobiology, ...

2002), but melanoma remains a malignancy predominantly refractory to anti-cancer therapies. New strategies are urgently needed, particularly as it has been predicted that growth and aging of the U ...

Most patients with pancreatic cancer are diagnosed in late-stage ... TNM staging was performed according to American Joint Committee on Cancer and Union for International Cancer Control TNM on the ...